ArticleBMJ open respiratory research2025
Integrating blood eosinophils and exhaled nitric oxide (FeNO) in asthma diagnostic pathways for adults and children: the PROPULSION SANTÉ observational study with translational sub-studies (DIVE, DIVE2)-protocols.
Article in BMJ open respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Diagnostic and Translational Values of Point-of-care Blood Eosinophils and Exhaled Nitric Oxide (FeNO) in People Referred by Primary Care for Suspected Asthma (DIVE)
PROPULSION SANTE: Inflammometry to Improve the Diagnostic Trajectory in Situations of Suspected Asthma in Children and Adults
Diagnosing Asthma With Clinically Accessible, Non-invasive, and Efficient Tests: a Child-inclusive Translational Investigation
Who cites it
1 citing paper in PubMed.
- Different Inflammatory Phenotypes and Immune Endotypes Drive Disease Heterogeneity in Asthma and COPD.Clinical reviews in allergy & immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionDiagnosing asthma requires confirmation by bronchodilator reversibility (BDR) with or without bronchial provocation testing (BPT). Despite being needed in 80% of suspected cases following BDR, BPT access remains limited in Canada. Type-2 (T2) inflammatory biomarkers (fractional exhaled nitric oxide (FeNO) and blood eosinophil count (BEC)) may be underutilised for BPT prioritisation and are insufficiently studied to support asthma diagnosis in real-world primary care, especially in children. We aimed to explore whether T2 biomarker-based prioritisation of BPT reduces diagnostic delays, and improves triage efficiency and guidance based on exacerbation risk. METHODS AND ANALYSIS: Three academic centres in Québec will measure inflammatory biomarkers alongside BDR and/or BPT interpretation for patients with suspected asthma referred by primary care providers (PROPULSION SANTÉ, NCT06981169). Consenting patients aged ≥6 years will undergo FeNO, BEC and BDR testing. If BDR is non-diagnostic, subsequent BPT will be prioritised for patients with ≥1 elevated biomarker (BEC ≥300 /µL, (FeNO ≥25 ppb if ≥12 years or FeNO ≥20 ppb if <12 years)); others will follow usual timelines. Reports to the referring healthcare providers will include standard interpretation of BDR/BPT and biomarker results to state exacerbation risk and suggested corticosteroid dosage. Asthma control and quality of life will be assessed at baseline and remotely at 4, 8 and 12 months. The primary outcome will be the delay from the reception of test request for the diagnosis of asthma patients with versus without elevated biomarker(s). Secondary outcomes include biomarkers' diagnostic performance, asthma control, quality of life, health benefits, cost-effectiveness, environmental impact and patient satisfaction. We aim to recruit 1500 patients to PROPULSION SANTÉ, with optional biobanking for translational sub-studies for 123 adults (DIVE, NCT05992519) and 123 children (DIVE2, NCT07011394). ETHICS AND DISSEMINATION: Study protocols were ethically approved CIUSSS de l'Estrie-CHUS #MP-31-2025-5593/MP-31-2024-5346; 2023-4791). Results will be communicated and submitted to peer-reviewed journals. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov (NCT06981169; NCT05992519; NCT07011394).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.